Abbott Expands Alzheimer's Diagnostics via Global Licensing Deal with ALZpath

Key Facts

In a strategic move reflecting the accelerating innovation in neurodegenerative diagnostics, Abbott has entered into a global licensing agreement with ALZpath. Under the terms of the deal, Abbott will incorporate ALZpath’s proprietary pTau217 antibody into the development of in vitro diagnostic (IVD) tests for early Alzheimer’s detection. This collaboration aims to leverage specialized antibody technology to enhance diagnostic accuracy on a global scale.

This partnership places Abbott in direct competition with industry peers like Roche and Quanterix, who are also racing to dominate the Alzheimer's blood-testing market, which is projected to exceed $10 billion by 2030 (per market research). The pTau217 protein is increasingly recognized as a gold-standard biomarker, providing Abbott with a significant technological edge over competitors in the medical device sector according to market data.

Regarding market performance, ABT stock closed at $88.41 (close June 18, 2026), trading between a high of $89.44 and a low of $87.76 during the session per market data. Investors should monitor how this integration impacts long-term diagnostic revenue, while keeping an eye on upcoming US economic catalysts that may influence healthcare sector volatility.